SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated September 1, 2023, serves as a regulatory notification to the market in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R. The report details the company's issued share capital and total voting rights as of August 31, 2023.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a capital structure notification.
Material Changes
The filing does not report material changes in financial performance or operations compared to prior periods. It solely updates the share capital figures for regulatory compliance.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, contingencies, or unusual items. Its sole purpose is to inform shareholders of the denominator to be used for calculating notification thresholds under FCA rules.
Key Facts for Investor Verification
- Issued Share Capital: As of August 31, 2023, GSK Plc had 4,312,084,743 Ordinary Shares of 31 1/4 pence each.
- Treasury Shares: 217,068,169 Ordinary Shares were held in Treasury.
- Total Voting Rights: The total number of voting rights is 4,095,016,574.
- Regulatory Use: This voting rights figure is the required denominator for shareholders determining if they must notify the company of their interest or changes thereto.